Clutch of Cells Strong Indicator of Chronic Graft vs Host Disease

Finally - a potentially very reliable biomarker could help doctors determine which bone marrow transplantation patients are at highest risk of developing one of the deadliest diseases associated with that procedure.

According to researchers at the Stanford University School of Medicine, if a so-called clutch of cells can be found in the blood of a male patient after he has received cells from a female donor, that patient is almost certain to develop chronic graft-versus-host disease (cGVHD), a disease in which the newly grafted cells attack body tissue in the recipient.

Says senior study author David Miklos, MD, PhD, assistant professor of medicine:

"The overwhelming majority of patients who have these cells in their blood either have or will develop cGVHD within one to three months."

The study has appeared online in the Proceedings of the National Academy of Sciences. The findings represent the first predictive indicator for the onset of cGVHD.

Female-to-male transplants: Higher risk of cGVHD, lower risk of relapse

While sex-matched transplants are generally preferred, they are not always possible. In the case of female-to-male bone marrow transplants, the recipients are at a 40 percent higher risk of developing cGVHD than sex-matched transplants. These patients are also at a reduced risk of cancer relapse by 35 percent.

These findings should help to lead to more effective methods of treating cGVHD as well as therapies that could help lessen the severity of the disease or head it off altogether.

Source: MNT

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap